Fig. 7From: Anti-vascular endothelial growth factor for neovascular age-related macular degeneration: a meta-analysis of randomized controlled trialsRanibizumab versus control. Mean change in best corrected visual acuity (in letters) from baseline comparing ranibizumab with control at 1 and 2Â years. IV, inverse variance; SD, standard deviationBack to article page